Black Diamond Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Black Diamond Therapeutics

12/05/2022 12:43

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a
quarterly
adjusted loss of 70 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 75 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 70 cents​.
    * The mean earnings estimate of analysts had risen by
about 26.9%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Black Diamond Therapeutics Inc shares had fallen by 32.5%
this
quarter and lost 64.9% so far this year.
    * The company reported a quarterly loss of $25.51 million.
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $6.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 11:43 a.m.  ​All
figures in US dollars unless otherwise stated